Enanta Pharmaceuticals Announces Positive Phase 2b Results

Enanta Pharmaceuticals ( (ENTA) ) has shared an update.

On September 29, 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b study of zelicapavir in high-risk adults for the treatment of respiratory syncytial virus (RSV). The study demonstrated a clinically meaningful reduction in symptom duration, supporting further development towards a Phase 3 trial. This advancement positions Enanta strategically in the RSV treatment market, potentially addressing significant unmet needs for high-risk populations, including older adults and those with chronic heart or lung diseases.

The most recent analyst rating on (ENTA) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.

Spark’s Take on ENTA Stock

According to Spark, TipRanks’ AI Analyst, ENTA is a Underperform.

Enanta Pharmaceuticals’ overall stock score is primarily impacted by its poor financial performance, characterized by significant losses, high leverage, and cash flow issues. Technical analysis indicates bearish momentum, while valuation metrics highlight ongoing profitability challenges. The absence of earnings call data and corporate events further limits positive influences on the score.

To see Spark’s full report on ENTA stock, click here.

More about Enanta Pharmaceuticals

Enanta Pharmaceuticals operates in the biopharmaceutical industry, focusing on the research and development of small molecule drugs. The company is engaged in creating treatments for viral infections and liver diseases, with a particular emphasis on respiratory syncytial virus (RSV), hepatitis B, and COVID-19.

Average Trading Volume: 208,509

Technical Sentiment Signal: Sell

Current Market Cap: $168.9M

For detailed information about ENTA stock, go to TipRanks’ Stock Analysis page.